id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-285486-99trkti1	Abd-Elsalam, Sherief	Hydroxychloroquine in the Treatment of COVID-19: A Multicenter Randomized Controlled Study	2020-08-14		.txt	text/plain	2928	166	53	Univariate logistic regression analysis showed that HCQ treatment was not significantly associated with decreased mortality in COVID-19 patients. So, adding HCQ to standard care did not add significant benefit, did not decrease the need for ventilation, and did not reduce mortality rates in COVID-19 patients. 1. Hydroxychloroquine group: This group included 97 patients who received HCQ 400 mg twice daily (in day 1) followed by 200 mg tablets twice daily added to the standard of care treatment adopted by the Egyptian MOH for 15 days. 18 Although cardiac toxicity is a known adverse event requiring monitoring during treatment, HCQ showed promise in treating SARS-CoV-2-infected patients with multiple comorbidities including coronary artery disease. 12 studied the change in symptom severity over 14 days in nonhospitalized patients between HCQ and control groups and did not find any significant difference (P = 0.12).	./cache/cord-285486-99trkti1.txt	./txt/cord-285486-99trkti1.txt